Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact...
Dare Bioscience, Inc. (DARE)
Last dare bioscience, inc. earnings: 8/14 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.darebioscience.com/investor-relations
Company Research
Source: GlobeNewswire
SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced it will host a live webinar on Monday, November 17, 2025, on the DARE to PLAY™ difference with leading sexual health and menopause clinicians Dr. Sheryl Kingsberg and Dr. Jim Simon. Event Details: Title: The DARE to PLAY™ Difference Date: Monday, November 17, 2025Time: 12:00pm ETRegistration and Access: https://cvent.me/KO1obd DARE to PLAY™ Sildenafil Cream is a first-of-its-kind topical sildenafil formulation designed specifically for women to enhance genital blood flow and arousal response. Supported by clinical data demonstrating increased genital blood flow within 10 to 15 minutes of application and improvements in arousal sensations based on clinically validated and FDA-reviewed endpoints, DARE to PLAY™ represents the first and only evi
Show less
Read more
Impact Snapshot
Event Time:
DARE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DARE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DARE alerts
High impacting Dare Bioscience, Inc. news events
Weekly update
A roundup of the hottest topics
DARE
News
- Dare Bioscience (NASDAQ:DARE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-MaximizationGlobeNewswire
- Daré Bioscience Receives $3.6 Million in Additional Grant FundingGlobeNewswire
- Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript [Seeking Alpha]Seeking Alpha
- Earnings To Watch: Dare Bioscience Inc (DARE) Reports Q3 2025 Result [Yahoo! Finance]Yahoo! Finance
DARE
Earnings
- 11/13/25 - Beat
DARE
Analyst Actions
- 12/2/25 - HC Wainwright
DARE
Sec Filings
- 12/1/25 - Form 8-K
- 11/25/25 - Form 1-A
- 10/6/25 - Form SCHEDULE
- DARE's page on the SEC website